That's a great argument, I'm not so sure I buy it entirely.
A significant portion of R&D is funded by the government through grants and public research projects. Much of the fundamental research is done in academic settings using public money. Pharma companies spend most of their R&D budgets on the "D" meaning pharmaceutical companies are increasingly in the business of running clinical trials and marketing drugs rather than plowing the hard ground for new discoveries.
The costs are high, certainly, but pharma only spends about 10-15% of their budgets on R&D, they spend twice as much on marketing. I can only wonder how much more they spend lobbying congress. In this sense the basic research costs are socialized while the profits are privatized.
The drug being discussed in this thread being exhibit A.
Gilead announced on Monday it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir. It is estimated in a May
report that U.S. taxpayers contributed at least $70.5 million to the development of remdesivir. There is one estimate that Gilead could still profit if they were charging $310 per course (a tenth of what they have announced).
Sen. Bernie Sanders (I-Vt.) condemned Gilead's price-tag as "beyond disgusting."
"Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic.. Coronavirus treatment must be free to all."
I would disagree with the 'free' part from Sen. Sanders but a reasonable figure between free and $3120 hovering around $300-500 would seem to be capitalistic and serve the public in my opinion.
(
supportive reading linked here)